Meet the Team

The PredictImmune Team

The PredictImmune team features a number of highly qualified research specialists with many years of research experience between them. To find out more about PredictImmune’s team of specialists and to see the experience and professionalism they bring to all of their research please read the team bios.

Professor Kenneth Smith

Professor Kenneth Smith

BMedSci, MBBS, PhD, MA, FRCP, FRCPA, FRACP, FHEA, FMedSci

More about Kenneth

Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Andrew P Sandham

Andrew P Sandham

Chairman

More about Andrew

Andrew has more than 30 years’ experience in co-founding and building start-up businesses in the biotechnology sector in the UK and US. He has served in chairman, non-executive and executive roles with UK and US biotech start-up companies, including Cantab Pharmaceuticals, Hexagen, Signature Bioscience, Novacta, Ionix Pharmaceuticals, NeurAxon, Syntaxin, Synosia, Kymab, Bicycle Therapeutics, 14M Genomics and PredictImmune. He has also worked within venture capital firms Abingworth and Syncona and currently serves as a director of Plant Bioscience (PBL) and is deputy chairman of the Cambridge Enterprise Investment Committee.
Paul Kinnon

Paul Kinnon

Chief Executive Officer

More about Paul

Paul has over 25 years’ experience in the global life sciences industry, with the past 15 years of his executive career focused on Clinical Diagnostics. He has held leadership positions with Transgenomic, ZyGEM Corp., Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, generating more than $60m in funding, creating global partnerships and increasing shareholder return. Paul has a proven strategic and commercialisation track record, in addition to over ten years’ international Board experience, in both private and public companies, with significant expertise in Corporate governance, Corporate restructuring, M&A and divestiture activities.
Eoin McKinney BA, MBChB, MRCP, PhD

Eoin McKinney BA, MBChB, MRCP, PhD

Chief Scientific Officer

More about Eoin

Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Paul Lyons BSc, PhD

Paul Lyons BSc, PhD

VP Platform Delivery

More about Paul

Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Karin Schmitt PhD

Karin Schmitt PhD

VP Research Operations

More about Karin

Karin Schmitt is a trained scientist with over twenty-five years of experience and sustained track record of successful leadership of people and management of a scientific function within the life sciences, biotech and diagnostics industry, including Millennium, ThermoFisher and Horizon Discovery. She has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on the diagnostics market. She has additional experience in legal, commercial and regulatory. At PredictImmune her focus is on transferring the technology from a university setting to a commercial product in a regulated environment.

Get in Touch

If you have an enquiry, contact PredictImmune using the following contact details. Alternatively, submit the enquiry form and one of our team will be in touch as soon as possible to see how we can meet your needs.

+44(0)1223 804 195
E info@predictimmune.com

About
PredictImmune develops pioneering tools for guiding treatment options in immune mediated diseases such as Inflammatory Bowel Disease.

Contact
T +44 (0)1223 804 195
E info@predictimmune.com
PredictImmune Ltd, Maia, Building 270
Babraham Research Campus
Cambridge CB22 3AT
United Kingdom